About
Thesian Bio develops in vivo CAR-T and CAR-M cell therapies using lentiviral vector technology to directly target immune cells within patients for treatment of hematologic cancers, solid tumors, and autoimmune disorders.
Explore Thesian Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.